Growing Market Adoption AppliedVR has successfully obtained FDA breakthrough designation and de novo authorization for its flagship RelieVRx device, positioning it as a leader in immersive therapeutics for chronic pain treatment and creating opportunities to expand into diverse healthcare settings.

Expanding Reimbursement Access With the establishment of a unique CMS code and coverage category around RelieVRx, there is significant potential to increase payer acceptance and reimbursement, facilitating broader adoption among hospitals, clinics, and workers' compensation programs.

Strategic Partnerships and Expansions Recent collaborations with VHA, veterans, and workers' compensation sectors highlight growth avenues. Targeting other health systems and insurance payers presents opportunities to scale use of immersive therapeutics for various patient populations.

Market Position and Financial Strength With over 50 million in revenue and nearly 100 million in funding, AppliedVR is financially positioned to accelerate sales efforts, invest in new product features, and strengthen relationships within the healthcare industry to penetrate new markets.

Technological and Clinical Validation AppliedVR’s validated, FDA-cleared platform backed by clinical trials demonstrates efficacy for chronic lower back pain, making it an attractive solution for healthcare providers seeking innovative, non-pharmacological pain management options.